Optimizing upstream processing to improve consistency and scalability in viral vector production

“It is exciting to build something from an early stage...and getting to enjoy the results of that work.”

Jokūbas Leikauskas, Editor, BioInsights, speaks to Katerina Rigaki, Upstream Manager PD Vector, Autolus Therapeutics, about overcoming the technical and logistical challenges in cell and gene therapy (CGT) manufacturing, particularly around transient transfection, raw material variability, and scalability in adherent and suspension systems.

Please enter your email to access content Read now